TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Healthy Controls~Inclusion Criteria:~* Male or female, age 19-65, no apparent signs of hepatobiliary diseases~Exclusion Criteria:~* Levels higher than 50, 56, 78 U/L for ALT, AST, and GGT, respectively.~Patient Population~Inclusion Criteria:~* Male or female, age 19-65, visiting the UNMC hepatology clinic for treatment from hepatobiliary diseases~Exclusion Criteria:~* MELD score less than 6

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Controls (Type: None): Male or female, age 19-65, no apparent signs of hepatobiliary diseases
- Patients with hepatobiliary diseases (Type: None): Male or female, age 19-65, visiting the UNMC hepatology clinic for treatment from hepatobiliary diseases

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Study of Two Splints Used for Treatment of Acute Temporomandibular Pain.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, non-chronic orofacial pain~Exclusion Criteria:~* Pregnancy, chronic orofacial pain, dental treatment need, dental pain, edentulous space larger than 5mm, more than three molars missing in the same quadrant, rheumatic disease, Injury/operation in maxillofacial area.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aqualizer (Type: ACTIVE_COMPARATOR): None
- Soft splint (Type: ACTIVE_COMPARATOR): elastic splint made of copolyester foil
- Counselling (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: S9709, Laser Surgery Plus Radiation Therapy in Treating Patients With Early Stage Cancer of the Larynx

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven, newly diagnosed, untreated stage I, II, or selected stage III (T1-T2, N1, M0) squamous cell carcinoma of the supraglottic larynx Bidimensionally measurable disease No metastatic or stage III T3 disease No immediate life-threatening complications of the disease~PATIENT CHARACTERISTICS: Age: Over 18 Performance status: SWOG 0 or 1 Life expectancy: Not specified Hematopoietic: WBC greater than 3,500/mm3 Platelet count greater than 50,000/mm3 Hemoglobin greater than 10.0 g/dL Hepatic: Not specified Renal: Not specified Cardiovascular: At least 3 months since prior myocardial infarction No uncontrolled congestive heart failure No unstable or uncontrolled angina Other: No prior malignancy except for the following: Adequately treated basal cell or squamous cell skin cancer In situ cervical cancer Other cancer for which the patient has been disease-free for at least five years No history of prior laryngeal cancer No history of primary tumors of any aerodigestive tract site except disease site All fertile patients must use an effective contraceptive method Must be medically able to undergo general anesthesia No psychological, familial, sociological or geographical conditions that do not permit medical follow-up and compliance with study protocol No other unstable or pre-existing major medical condition~PRIOR CONCURRENT THERAPY: No prior treatment for squamous cell carcinoma of the supraglottic larynx

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transoral CO2 laser laryngectomy and RT (Type: EXPERIMENTAL): Transoral CO2 laser supraglottic laryngectomy and irradiation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D Supplementation Requirement in Obese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy men or women between the ages of 18 and 70 years old who are enrolled in our Weight Management Program with baseline BMI \> 30 Kg/m2.~Exclusion Criteria:~* Pregnancy,~* Serum 25(OH)D level greater than 80 nmol/L,~* Hypercalcemia (serum calcium level greater than the upper limit of normal),~* Recent surgery or illness,~* Those with chronic use of medications that influence calcium/vitamin D metabolism such as anti-convulsants, lithium and steroids. Thiazide diuretics for hypertension will be acceptable.~* Subjects with sarcoidosis will be excluded.~* Those who do not qualify to participate in the Weight Management Program will be excluded. They include subjects with active substance abuse and unstable cardiac disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Half of subjects will be randomized to the placebo group.
- Vitamin D3 (Type: ACTIVE_COMPARATOR): This is the study group that receives Vitamin D supplementation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage IV adenocarcinoma or transitional cell carcinoma of the kidney that is unlikely to respond to existing therapy~* Measurable disease by MRI or CT scan~* Tumor must be more than 2 cm for lymph nodes in head, neck, axillary, inguinal, or femoral areas and at least 0.5 cm for other locations~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* No hepatic insufficiency~* Bilirubin no greater than 2.5 mg/dL~* SGOT and SGPT no greater than 5 times upper limit of normal~Renal:~* No renal insufficiency~* Creatinine no greater than 2.5 mg/mL~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No known chronic heart failure~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No severe lung disease, such as chronic obstructive pulmonary disease~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* Not a high medical or psychiatric risk~* No concurrent nonmalignant systemic disease that would preclude therapy~* No active infection~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy~* No concurrent immunomodulatory agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~* No concurrent antineoplastic agents~Endocrine therapy:~* Concurrent corticosteroids allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy and recovered~Surgery:~* Recovered from prior surgery~Other:~* Prior cytodifferentiating agents allowed~* No prior antineoplastons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Corneal De-epithelization Associated With a Therapeutic Photokeratectomy in Patients With Evolutive Keratoconus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged from 15 to 45 years old~* Patients with an evolutive keratoconus~* Planned intervention (de-epithelization and photokeratectomy)~Exclusion Criteria:~* Contra-indication to de-epithelization (active scarring corneal lesion)~* Pregnant women and breastfeeding~* Absence of the written consent to participate in the trial

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Evolutive keratoconus (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years~* Metastatic lung carcinoma~* With: - EGFR gene mutation~* Or at least 2 predictive factors of addictive mutation (Women, non smocking or cessation \> 3 years, Asiatic, lung adenocarcinoma)~* Eligible for 1st line treatment~* Performance status ≤ 3~* Available tumor sample or tumor reachable for biopsy~* With informed and signed consent~* Affiliation to the National Social Security System~Exclusion Criteria:~* Previous radiotherapy treatment in months preceding initials samples~* Pregnant or breastfeeding women~* Patient not able to give consent or unwilling to provide consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- study procedure (Type: EXPERIMENTAL): Clinical exam. Liquid biopsy. Diagnostic exam (biopsy and imagery). 1st line treatment. tumor evaluation. Biopsy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Research Study of Greater Occipital Nerve Block As A Treatment For Prolonged Migraine Attacks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IHS criteria for episodic migraine~* Presenting to clinic in migraine status, meaning the migraine has continued for greater than or equal to 3 days but less than 3 months.~* Pain must be reported as at least moderate pain level at time of injections~Exclusion Criteria:~A subject is ineligible to participate in this study if he/she satisfies any of the following criteria:~* Subjects who have received greater occipital nerve blocks in the past~* Subjects who in their own or the investigator's opinion are unable to describe their symptoms~* Subjects who are pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Lidocaine/Bupivicaine (Type: ACTIVE_COMPARATOR): None
- saline (Type: PLACEBO_COMPARATOR): matching volume of saline injected

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All normal donors for patients undergoing allogeneic peripheral blood stem cell (PBSC) for hematologic diseases will be invited to participate in this research trial.~* All patients must meet criteria for transplantation.~* Final eligibility will be determined by the health professionals conducting this clinical trial.~Exclusion Criteria:~* Donors for patients undergoing selected or manipulated PBSC grafts are not eligible.~* Donors who are pregnant or lactating females and donors with a known hypersensitivity to either G-CSF or GM-CSF will be excluded from this study.~* Final eligibility will be determined by the health professionals conducting this clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- G-CSF(Granulocyte Colony-Stimulating Factor ) (Type: ACTIVE_COMPARATOR): Single use of G-CSF(Granulocyte Colony-Stimulating Factor ) G-CSF 7.5 µg/kg twice a day
- Granulocyte CSF+Granulocyte Macrophage CSF (Type: ACTIVE_COMPARATOR): Combined use of G-CSF(Granulocyte Colony-Stimulating Factor ) and GM-CSF (Granulocyte Macrophage Colony Stimulating Factor) (G-CSF 7.5 µg/kg / GM-CSF 7.5 µg/kg.)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Pain and Skin Closure Methods After Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-44~* Any race~* Any parity~* Scheduled Cesarean Section~* Neuraxial analgesia~Exclusion Criteria:~* Diabetes Mellitus~* Maternal Connective Tissue Disorder~* Maternal Steroid Use

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 44 Years
- Healthy Volunteers: t

Study Arms:
- INSORB staples skin closure (Type: ACTIVE_COMPARATOR): Women undergoing cesarean section delivery will have skin closure with INSORB staples.
- Monocryl skin closure (Type: ACTIVE_COMPARATOR): Women undergoing cesarean section delivery will have skin closure with Monocryl.
- Vicryl skin closure (Type: ACTIVE_COMPARATOR): Women undergoing cesarean section delivery will have Vicryl skin closure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Feasibility Study of Confocal Microendoscopy in the Evaluation of Gastrointestinal Neoplasia -Project 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patient 18 years or older~* colonoscopy for screening or surveillance of polyps or disease of colon~* anoscopy because of suspected or known anal dysplasia or neoplasia~Exclusion Criteria:~* patient unable to provide informed consent~* patient found unfit for standard colonoscopy or anoscopy with biopsies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluorescein (Type: EXPERIMENTAL): Confocal imaging using contrast agent fluorescein
- Proflavine hemisulfate (Type: EXPERIMENTAL): confocal imaging using contrast agent proflavine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Medicine Adherence and Effects on Transplants With Pilloxa's Electronic Pillbox

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient had an organ (liver or kidney) transplanted.~* Patient who wishes to participate in the study and who is able to understand, read, write and give written informed consent in the Swedish or English language. For persons under the age of 18, the guardians must understand, read, write and give written informed consent in the Swedish or English language.~* Ongoing daily immunosuppressive medication that is expected to continue during the study period.~* Handles medication by herself or, in the case of children, that medication is handled by the guardian.~* The patients doses of immunosuppressants fits into the chambers of the product.~* The patient's medicine ordination is not expected to change more often than once weekly.~* Owns and uses a compatible smartphone, option for underage children that guardians hold a compatible smartphone.~Exclusion Criteria:~* Suffers from dementia, neurological disease or other cognitive impairment which causes problems in understanding instructions or managing medication independently.~* Physical inability to use the product as intended.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pilloxa Pillbox (Type: EXPERIMENTAL): None
- Non active Pilloxa Pillbox (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Internet Intervention for Diabetes Distress

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged between 25-80.~* Have type 2 diabetes for five years or more.~* Have internet access~Exclusion Criteria:~* Outside of age criteria.~* Does not have type 2 diabetes for five years or more.~* No internet access

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Space from Diabetes (Type: EXPERIMENTAL): Participants will be assigned the 'Space from Diabetes' intervention in a supported mode for 8 weeks. Participants are assigned a clinical supporter, who will be a psychological well-being practitioner in an NHS Mental Health Service. As the participant works through the programme content, the supporter will provide them with a review of their progress and interactions with the platform 6 times over the 8 week supported period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Preventing Alcohol Withdrawal With Oral Baclofen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (\>21) admitted to inpatients units of 1 of 3 Essentia Health hospitals~* Patient placed on AWS watch protocol by admitting physicians.~Exclusion Criteria:~* Unable to provide informed consent~* Unable to take swallow oral medications (tube-fed patients are to be excluded)~* Admitted for AWS or with Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar) score \>8 at baseline~* No alcohol intake for ≥ 48 hours or AUDIT score \<12 at baseline~* Baclofen use at baseline~* Baclofen sensitivity~* Hospital discharge anticipated in within 48 hours~* Pregnant or breast feeding (urine pregnancy test required of women of child-bearing potential)~* Other active drug dependence (except tobacco)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo every eight hours as inpatients for 72 hours or until discharge if less than 72 hours.
- Baclofen (Type: ACTIVE_COMPARATOR): Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues